1. 1037. Qualitative Findings from a Hybrid III Implementation-Effectiveness Study to Explore Perspectives of Health-care Staff on Early Implementation of Cabotegravir and Rilpivirine Long Acting (CAB+RPV LA) Injectable HIV treatment in the US (CUSTOMIZE). (31st December 2020) Authors: Czarnogorski, Maggie; Garris, Cindy; Wannamaker, Paul; D'Amico, Ronald; Selenski, Carolyn; Williams, Will; McHorney, Colleen A; Stassek, Larissa; Wohlfeiler, Michael; Sinclair, Gary I; Mena, Leandro A; Margolis, David Journal: Open forum infectious diseases Issue: Volume 7:Number 1(2020) Supplement Page Start: S549 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 1288. US Healthcare Provider Perspectives on the initiation of cabotegravir and rilpivirine long-acting (CAB+RPV LA) in an observational real-world study (BEYOND). (15th December 2022) Authors: Hsu, Ricky K; Phoenix, John; Sinclair, Gary I; Gupta, Samir K; Puga, Ana; Nguyen, Kaitlin; Schubert, Catherine K; Merrill, Deanna; Richardson, David; Nelson, Kate; Reynolds, Maria; Zografos, Laurie; Jean-Louis, Ashley; Garris, Cindy Journal: Open forum infectious diseases Issue: Volume 9:(2022)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗